β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer

Curr Cancer Drug Targets. 2022;22(7):537-540. doi: 10.2174/1568009622666220427121127.

Abstract

Cancer, one of the major health problems all over the world, requires more competent drugs for clinical use. One recent possible chemotherapeutic drug under research is β-lapachone. β- lapachone (1,2-naphthoquinone) has promising activity against those tumors showing raised levels of Nicotinamide di-phosphate Quinone Oxidoreductases-1 (NQO1). NQO1 is found to be up-regulated in pancreatic tumor cells, and thus β-lapachone could generate cytotoxicity in various cancers like pancreatic tumors. β-lapachone harborage independent growth and clonogenic cell survival in agar. The cell-killing effects of β-lapachone can be stopped by using dicumarol, an inhibitor of NAD(P)H Quinone Oxidoreductases-1. In previously established pancreatic cancer xenografts in mice, β- lapachone inhibited the tumor growth when given orally rather than when combined with cyclodextrin to improve its bioavailability.

Keywords: NAD(P)H quinone oxidoreductase-1; cyclodextrins; human pancreatic cancer; quinones; reactive oxygen species; β-lapachone.

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Apoptosis
  • Cell Line, Tumor
  • Humans
  • Mice
  • NAD(P)H Dehydrogenase (Quinone)
  • Naphthoquinones* / pharmacology
  • Naphthoquinones* / therapeutic use
  • Niacinamide / therapeutic use
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / pathology
  • Phosphates / pharmacology
  • Phosphates / therapeutic use

Substances

  • Antineoplastic Agents
  • Naphthoquinones
  • Phosphates
  • Niacinamide
  • beta-lapachone
  • NAD(P)H Dehydrogenase (Quinone)
  • NQO1 protein, human